Catalyst Dossier · compiled by CeliA 🧫

QUEST DIAGNOSTICS INC (DGX)

Services-Medical Laboratories · market cap $21.6B · as of 2026-06-25

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-23

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Quest Diagnostics (DGX) is a Fortune 500 clinical laboratory services company with ~$11B in annual revenue, 56,000 employees, and operations across the U.S., Puerto Rico, Mexico, and Brazil. The company is notable here for an anomalous data point: its listed 'lead asset' is Carboplatin in Phase 2 for Ovarian Neoplasms, which is a well-established chemotherapy agent entirely inconsistent with Quest's core diagnostics business model. The near-term catalyst is a Q2 2026 earnings release on July 23.

The catalyst path

2026-07-23Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Carboplatin	Phase 2	Ovarian Neoplasms

Price & technical context

3-month

+10.2%

6-month

+23.1%

12-month

+20.3%

52-wk range

$166.42–$216.02

vs 50-day MA

+9.7%

vs 200-day MA

+13.4%

Realized vol

23.3%

Max drawdown

-11.9%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for DGX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.